Cholinesterase inhibitors and memantine for symptomatic treatment of dementia

BMJ (Online)

Volumn 344, Issue 7856, 2012, Pages

  Rodda, Joanne ^a,b   Carter, Janet ^a,b  

^a Havering Older People's Services   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR; COGNITION; CONSTIPATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FRONTOTEMPORAL DEMENTIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LONG TERM CARE; MIXED DEMENTIA; MONOTHERAPY; MULTIINFARCT DEMENTIA; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SOMNOLENCE; VOMITING; AGED; FEMALE; PRACTICE GUIDELINE; REVIEW;

AGED; CHOLINESTERASE INHIBITORS; DEMENTIA; DOPAMINE AGENTS; FEMALE; HUMANS; MEMANTINE; PRACTICE GUIDELINES AS TOPIC;

EID: 84860891561     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e2986     Document Type: Short Survey

References (27)

1. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211-25. (Pubitemid 352037861)
2. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol 2007;7:26.
3. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:244-51.
4. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-65.
5. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-69. (Pubitemid 47450281)
6. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, et al. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis 2010;21:843-51.
7. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47.
8. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217 . NICE, 2011.
9. National Collaborating Centre for Mental Health. Dementia: A NICE-SCIE Guideline on supporting people with dementia and their carers in health and social care . National Clinical Practice Guideline Number 42. NICE, 2006 amended 2011.
10. McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154.
11. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68:991-8.
12. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24. (Pubitemid 38101604)
13. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9. (Pubitemid 351536358)
14. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:11-21.
15. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
16. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782-92 (Pubitemid 47243710)
17. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-204. (Pubitemid 350294674)
18. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90. (Pubitemid 34310633)
19. McKeith I, del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6. (Pubitemid 32009817)
20. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18. (Pubitemid 39603164)
21. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-8.
22. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-77.
23. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-4. (Pubitemid 44967366)
24. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
25. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011;59:1019-31.
26. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67. (Pubitemid 46831690)
27. Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatric Treat 2007;13:178-84. (Pubitemid 351148920)